Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
04:05pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
01:33pm, Thursday, 07'th Apr 2022
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
03:58pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
01:33pm, Wednesday, 06'th Apr 2022
The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.
5% Yielding Dividend Aristocrats You'll Want To Own In The Coming Bear Market
06:20pm, Tuesday, 05'th Apr 2022 Seeking Alpha
The bond market is starting to signal that a recession and bear market could be coming in 2023 or 2024. Read more to see the 5% yielding dividends to own.
5% Yielding Dividend Aristocrats You'll Want To Own In The Coming Bear Market
02:20pm, Tuesday, 05'th Apr 2022
The bond market is starting to signal that a recession and bear market could be coming in 2023 or 2024.
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
11:48am, Tuesday, 05'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy P
Changes at Novartis Aimed at Boosting Shareholder Value
10:16am, Tuesday, 05'th Apr 2022
Novartis ( NVS , Financial) investors hope the organizational changes the company is making can shake loose some shareholder value. Since February 2020, Novartis stock has dropped nearly 12% while the
Accenture (ACN) Joins Health Data Collaborative, AI4BetterHearts
03:00pm, Monday, 04'th Apr 2022 Zacks Investment Research
Accenture's (ACN) goal behind joining the collaborative is to support and advance cardiovascular disease prevention through integrating innovation and emerging technologies.
Novartis integrates pharmaceuticals and oncology, targets savings of $1 billion
01:19am, Monday, 04'th Apr 2022
Novartis said on Monday it was integrating its pharmaceuticals and oncology units into an innovative medicines (IM) business to simplify its structure, targeting savings of at least $1 billion by 2024
3 CEOs to Invest In
01:00am, Saturday, 02'nd Apr 2022 The Motley Fool
Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
07:16pm, Friday, 01'st Apr 2022 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it
Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS
01:09pm, Friday, 01'st Apr 2022 Zacks Investment Research
FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
12:48pm, Friday, 01'st Apr 2022 Zacks Investment Research
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for
diabetic macular edema.
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
10:32am, Friday, 01'st Apr 2022
Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.
